How effective is brigatinib in treating lung cancer?

Brigatinib (Brigatinib) is a second-generation tyrosine kinase inhibitor (TKI) specifically targeting ALK (anaplastic lymphoma kinase) gene mutation-positive non-small cell lung cancer (NSCLC). Its efficacy has been verified in multiple clinical trials. The following is a review of the efficacy of brigatinib in the treatment of non-small cell lung cancer, combined with relevant clinical experimental data.

Clinical Trial Overview

The efficacy of brigatinib is primarily assessed through pivotal clinical trials, the most important of which is the ALTA trial (ALK-inhibitor Naïve Study of Brigatinib in ALK-positive Tumors). The trial was designed to evaluate the efficacy and safety of brigatinib (brigatinib) inALK mutation-positive non-small cell lung cancer.

ALTATest data

The ALTA trial is a global multi-center clinical trial that enrolled 274 patients with ALK mutation-positive non-small cell lung cancer. Some of these patients have not received ALK inhibitor treatment, and some have developed resistance to other ALK inhibitors (such as crizotinib) before using brigatinib.

Effectiveness results

1.Objective response rate (ORR): The objective response rate (ORR) of brigatinib in patients who had not received ALK inhibitor treatment was 54% . This result shows that more than half of patients who received brigatinib for the first time were able to achieve significant tumor shrinkage or stable disease.

2.Disease control rate (DCR): The disease control rate (DCR) of brigatinib is 85%. This means that most patients have effectively controlled their disease without significant disease progression after treatment with brigatinib.

3.Median progression-free survival (PFS): In the ALTA trial, brigatinib The median progression-free survival (PFS) for patients who had not received ALK inhibitor treatment was 24.7 months. For patients who had developed resistance to crizotinib, the median PFS was 8.9 months. This suggests that brigatinib has a longer disease control period in the treatment of ALK mutation-positive lung cancer and can significantly delay disease progression even in the context of drug resistance.

4.Median overall survival (OS): While the ALTA trial focused primarily on PFS, median overall survival (OS) data for brigatinib showed a positive trend. Preliminary data show that brigatinib can improve survival in patients, particularly in patients who have developed resistance to other ALK inhibitors.

Effects on the central nervous system

A significant advantage of brigatinib is its excellent penetration into the central nervous system (CNS ). In the ALTA trial, brigatinib (brigatinib) ’s efficacy against brain metastases was also verified. In patients with central nervous system metastases, brigatinib demonstrated a brain objective response rate (CNS-ORR) of 67%. This suggests thatbrigatinib (brigatinib)It has significant effects in controlling brain metastases, providing patients with additional treatment options.

Safety and Side Effects

The safety of brigatinib has also been evaluated in clinical trials. The most common side effects include nausea, diarrhea, fatigue and rash. Serious side effects such as pneumonia and interstitial lung disease (ILD), although uncommon, require close monitoring during treatment. The ALTA trial showed that brigatinib (brigatinib) was generally well tolerated, and most side effects could be effectively managed through dose adjustment or symptomatic treatment.

Brigatinib has shown significant efficacy in the treatment of ALK mutation-positive non-small cell lung cancer. Brigatinib demonstrated high objective response rates and long-term progression-free survival in patients who had not received an ALK inhibitor, according to data from the ALTA trial. In patients who have developed resistance to crizotinib, brigatinib also provides an effective treatment option, slowing disease progression. In addition, brigatinib's excellent penetration into the central nervous system makes it outstanding in dealing with brain metastases. Although there are some side effects, they are generally well tolerated and can be controlled with appropriate management measures. Brigatinib provides an effective treatment option for patients with ALK mutation-positive non-small cell lung cancer.